Jones Kristi 4

Accession 0001209191-23-023685

CIK 0001538210other

View on SEC.gov Company Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 8:39 PM ET

Size

43.7 KB

Accession

0001209191-23-023685

Insider Transaction Report

Form 4

Period: 2023-04-04

NexImmune, Inc.NEXI

Jones Kristi

Chief Operating Officer

Transactions

Award
Stock Option (right to buy)
2023-04-04+300,000→ 30,000 total
Exercise: $0.41Exp: 2033-04-03→ Common Stock (300,000 underlying)
Award
Stock Option (right to buy)
2023-04-04+161,500→ 161,500 total
Exercise: $1.23Exp: 2032-04-04→ Common Stock (161,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−84,207→ 0 total
Exercise: $17.00Exp: 2031-02-10→ Common Stock (84,207 underlying)
Award
Stock Option (right to buy)
2023-04-04+29,824→ 29,824 total
Exercise: $0.82Exp: 2031-02-10→ Common Stock (29,824 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−18,824→ 0 total
Exercise: $4.31Exp: 2029-06-17→ Common Stock (18,824 underlying)
Award
Stock Option (right to buy)
2023-04-04+18,824→ 18,824 total
Exercise: $1.23Exp: 2029-06-17→ Common Stock (18,824 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−24,499→ 0 total
Exercise: $4.31Exp: 2028-03-18→ Common Stock (24,499 underlying)
Award
Stock Option (right to buy)
2023-04-04+24,499→ 24,499 total
Exercise: $1.23Exp: 2028-03-18→ Common Stock (24,499 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−3,715→ 0 total
Exercise: $2.58Exp: 2028-09-24→ Common Stock (3,715 underlying)
Award
Stock Option (right to buy)
2023-04-04+3,715→ 3,715 total
Exercise: $1.23Exp: 2028-09-24→ Common Stock (3,715 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−456,000→ 0 total
Exercise: $4.22Exp: 2032-04-04→ Common Stock (456,000 underlying)
Award
Stock Option (right to buy)
2023-04-04+294,500→ 294,500 total
Exercise: $0.82Exp: 2032-04-04→ Common Stock (294,500 underlying)
Award
Stock Option (right to buy)
2023-04-04+54,383→ 54,383 total
Exercise: $1.23Exp: 2031-02-10→ Common Stock (54,383 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−88,156→ 0 total
Exercise: $2.58Exp: 2028-07-30→ Common Stock (88,156 underlying)
Award
Stock Option (right to buy)
2023-04-04+88,156→ 88,156 total
Exercise: $1.23Exp: 2028-07-30→ Common Stock (88,156 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-04-04−15,743→ 0 total
Exercise: $2.42Exp: 2027-03-02→ Common Stock (15,743 underlying)
Award
Stock Option (right to buy)
2023-04-04+15,743→ 15,743 total
Exercise: $1.23Exp: 2027-03-02→ Common Stock (15,743 underlying)

Footnotes (8)

[F1]25% of this option shall vest and become exercisable on April 4, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Jones's continued service to the corporation on each vesting date.
[F2]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 5, 2022, 25% of which will vest on the first anniversary of the grant date, and the remainder of the options will vest in equal monthly installments over the remaining 36 months, subject to Ms. Jones's continued service on each vesting date.
[F3]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2022, of which 43,857 shares vested, and the remainder of the options will vest in equal monthly installments such that on February 11, 2025, all shares subject to the option shall be vested, subject to Ms. Jones's continued service on each vesting date.
[F4]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 18, 2019, of which 17,647 shares vested, and the remainder of the options will vest in equal monthly installments such that on June 18, 2023, all shares subject to the option shall be vested, subject to Ms. Jones's continued service on each vesting date.
[F5]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested.
[F6]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on September 25, 2018, of which all of the shares subject to such option have vested.
[F7]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on July 31, 2018, of which all of the shares subject to such option have vested.
[F8]The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. On January 23, 2019 Ms. Jones exercised her right to purchase 31,636 shares subject to the original option.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

NexImmune, Inc.

CIK 0001538210

→

Entity typeother

Related Parties

filerCIK 0001843849

Filing Metadata

Form type: 4
Filed: Apr 5, 8:00 PM ET
Accepted: Apr 6, 8:39 PM ET
Size: 43.7 KB

View on SEC.gov